Home page Home page

Tasigna
nilotinib

Package leaflet: Information for the user


Tasigna 50 mg, 150 mg and 200 mg hard capsules

nilotinib


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

The other ingredients are:

Capsule content: Lactose monohydrate, crospovidone type A, poloxamer 188, colloidal anhydrous silica, magnesium stearate

Capsule shell: Gelatin, titanium dioxide (E171), yellow iron oxide (E172)

Printing ink: Shellac (E904), dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, potassium hydroxide, red iron oxide (E172)


What Tasigna looks like and contents of the pack

Tasigna 50 mg is supplied as hard capsules. The hard capsules are red/light yellow. A black imprint is stamped on each hard capsule (“NVR/ABL”).

Tasigna 150 mg is supplied as hard capsules. The hard capsules are red. A black imprint is stamped on

each hard capsule (“NVR/BCR”).

Tasigna 200 mg is supplied as hard capsules. The hard capsules are light yellow. A red imprint is stamped on each hard capsule (“NVR/TKI”).


Tasigna 50 mg hard capsules are available in a pack containing 120 hard capsules (3 packs of 40 hard capsules).

Tasigna 150 mg hard capsules are available in packs containing 28 or 40 hard capsules and in multipacks of 112 hard capsules (comprising 4 cartons, each containing 28 hard capsules), 120 hard

capsules (comprising 3 cartons, each containing 40 hard capsules) or 392 hard capsules (comprising 14 cartons, each containing 28 hard capsules).

Tasigna 200 mg hard capsules are available in a wallet containing 28 hard capsules and in a carton

containing 28 or 40 hard capsules. Tasigna is also available in multipacks of 112 hard capsules (comprising 4 wallets, each containing 28 hard capsules), 112 hard capsules (comprising 4 cartons, each containing 28 hard capsules), 120 hard capsules (comprising 3 cartons, each containing 40 hard capsules) or 392 hard capsules (comprising 14 cartons, each containing 28 hard capsules).


Not all packs may be marketed in your country.

Marketing Authorisation Holder

Novartis Europharm Limited Vista Building

Elm Park, Merrion Road Dublin 4

Ireland


Manufacturer

Novartis Farmacéutica SA

Gran Via de les Corts Catalanes, 764 08013 Barcelona

Spain


Novartis Pharma GmbH Roonstraße 25

D-90429 Nuremberg Germany


image

Lek d.d., PE PROIZVODNJA LENDAVA

Trimlini 2D Lendava, 9220

Slovenia


image

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11

Lietuva

SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50


България

Novartis Bulgaria EOOD Тел.: +359 2 489 98 28

Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11


Česká republika

Novartis s.r.o.

Tel: +420 225 775 111

Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00


Danmark

Novartis Healthcare A/S Tlf: +45 39 16 84 00

Malta

Novartis Pharma Services Inc. Tel: +356 2122 2872


Deutschland

Novartis Pharma GmbH Tel: +49 911 273 0

Nederland

Novartis Pharma B.V. Tel: +31 88 04 52 555


Eesti

SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810

Norge

Novartis Norge AS Tlf: +47 23 05 20 00


Ελλάδα

Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12

Österreich

Novartis Pharma GmbH Tel: +43 1 86 6570

España

Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00

Polska

Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888


France

Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00

Portugal

Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600


Hrvatska

Novartis Hrvatska d.o.o. Tel. +385 1 6274 220

România

Novartis Pharma Services Romania SRL Tel: +40 21 31299 01


Ireland

Novartis Ireland Limited Tel: +353 1 260 12 55

Slovenija

Novartis Pharma Services Inc. Tel: +386 1 300 75 50


Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439


Italia

Novartis Farma S.p.A. Tel: +39 02 96 54 1

Suomi/Finland

Novartis Finland Oy

Puh/Tel: +358 (0)10 6133 200


Κύπρος

Novartis Pharma Services Inc. Τηλ: +357 22 690 690

Sverige

Novartis Sverige AB Tel: +46 8 732 32 00


Latvija

SIA Novartis Baltics Tel: +371 67 887 070

United Kingdom (Northern Ireland)

Novartis Ireland Limited Tel: +44 1276 698370


This leaflet was last revised in


. There are also links to other websites about rare diseases and treatments.